We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Question That Doesn't Seem to Go Away: Cancer Risk of Anti-TNF Therapy.
- Authors
Ledder, Oren
- Abstract
Anti-tumor necrosis factor (TNF) therapy has revolutionized the treatment of inflammatory bowel disease (IBD) over the past two decades; for much of this period, the unresolved question of the potential cancer risk of this class of drug has been overshadowed by its therapeutic successes. Patients exposed to anti-TNF monotherapy had a pooled incidence rate ratio of 1.52 (95% CI 1.06-2.19) compared with patients with IBD unexposed to anti-TNF and thiopurines. Nevertheless, and most recently, a systematic review of 28 observational cohort studies including nearly 300,000 patients with IBD found no association between anti-TNF therapy and malignancies in all but one of the studies analyzed [[9]].
- Subjects
DISEASE risk factors; CROHN'S disease; INFLAMMATORY bowel diseases; TUMOR necrosis factors
- Publication
Digestive Diseases & Sciences, 2022, Vol 67, Issue 1, p6
- ISSN
0163-2116
- Publication type
Editorial
- DOI
10.1007/s10620-021-06883-w